49 related articles for article (PubMed ID: 11212905)
1. Pharmacokinetics of Dacarbazine and Unesbulin and CYP1A2-Mediated Drug Interactions in Patients With Leiomyosarcoma.
Gao L; Kaushik D; Van Tine BA; Ingham MA; Attia S; Meyer CF; Schwartz GK; Maliakal P; Baird JD; Ma J; Barrett R; D'Silva D; O'Keefe K; Kong R
Clin Transl Sci; 2023 Dec; 17(2):. PubMed ID: 38129988
[TBL] [Abstract][Full Text] [Related]
2. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.
Ballman KV; Buckner JC; Brown PD; Giannini C; Flynn PJ; LaPlant BR; Jaeckle KA
Neuro Oncol; 2007 Jan; 9(1):29-38. PubMed ID: 17108063
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide: a novel oral alkylating agent.
Danson SJ; Middleton MR
Expert Rev Anticancer Ther; 2001 Jun; 1(1):13-9. PubMed ID: 12113120
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide in malignant gliomas: current use and future targets.
Villano JL; Seery TE; Bressler LR
Cancer Chemother Pharmacol; 2009 Sep; 64(4):647-55. PubMed ID: 19543728
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma.
Rajkumar SV; Reid JM; Novotny PJ; Safgren SL; Scheithauer BW; Johnson PS; Nair S; Morton RF; Hatfield AK; Krook JE; Ames MM; Buckner JC;
J Neurooncol; 2000 Sep; 49(3):255-61. PubMed ID: 11212905
[TBL] [Abstract][Full Text] [Related]
6. Validated high-performance liquid chromatographic assay for simultaneous determination of dacarbazine and the plasma metabolites 5-(3-hydroxymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide.
Safgren SL; Reid JM; Rios R; Ames MM
J Chromatogr B Biomed Sci Appl; 2001 Apr; 754(1):91-6. PubMed ID: 11318431
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of dacarbazine (DTIC) in pregnancy.
Kantrowitz-Gordon I; Hays K; Kayode O; Kumar AR; Kaplan HG; Reid JM; Safgren SL; Ames MM; Easterling TR; Hebert MF
Cancer Chemother Pharmacol; 2018 Mar; 81(3):455-460. PubMed ID: 29305638
[TBL] [Abstract][Full Text] [Related]
8. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients.
Chiarion Sileni V; Nortilli R; Aversa SM; Paccagnella A; Medici M; Corti L; Favaretto AG; Cetto GL; Monfardini S
Melanoma Res; 2001 Apr; 11(2):189-96. PubMed ID: 11333130
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
Khan RB; Raizer JJ; Malkin MG; Bazylewicz KA; Abrey LE
Neuro Oncol; 2002 Jan; 4(1):39-43. PubMed ID: 11772431
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
11. Phase II North Central Cancer Treatment Group study of 2-cholorodeoxyadenosine in patients with recurrent glioma.
Rajkumar SV; Burch PA; Nair S; Dinapoli RP; Scheithauer B; O'Fallon JR; Etzell PS; Leitch JM; Morton RF; Marks RS
Am J Clin Oncol; 1999 Apr; 22(2):168-71. PubMed ID: 10199452
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
Dhodapkar M; Rubin J; Reid JM; Burch PA; Pitot HC; Buckner JC; Ames MM; Suman VJ
Clin Cancer Res; 1997 Jul; 3(7):1093-100. PubMed ID: 9815788
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer.
Reid JM; Stevens DC; Rubin J; Ames MM
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2393-8. PubMed ID: 9815639
[TBL] [Abstract][Full Text] [Related]
14. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.
Bower M; Newlands ES; Bleehen NM; Brada M; Begent RJ; Calvert H; Colquhoun I; Lewis P; Brampton MH
Cancer Chemother Pharmacol; 1997; 40(6):484-8. PubMed ID: 9332462
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
